Virax Biolabs Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering

LONDON, Aug. 16, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Chairman of the Board and Chief Executive Officer, James Foster will ring the Nasdaq Stock Market closing bell on Thursday, August 18, 2022. This comes after Virax began listing its common shares on the Nasdaq Capital Market on July 21, 2022.

The ceremony will begin at approximately 3:45 p.m. ET on August 18 and can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

"I am honored to ring the Nasdaq closing bell on behalf of the Virax team," commented James Foster. "The bell ringing ceremony is a great opportunity to celebrate the major milestone of the Company going public, and is representative of opening a new era for Virax. I am grateful to be joined by my talented team of colleagues and those who have supported us through all the stages of Virax's development over the years. Supported by our major progress and key strategic partnerships since the start of 2022, I am confident and excited for Virax's journey ahead."

Founded in 2013, Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.

Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus. For more information, please visit www.viraxbiolabs.com. 

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. 

Company Contact:
Virax Biolabs Group Limited
Phone: + +44 020 7788 7414
Email: [email protected]

Investor Relations Contact:
Russo Partners, LLC
Maxim Jacobs, CFA
(646) 942-5591
Email: [email protected]

SOURCE Virax Biolabs